CNS Pharmaceuticals Inc. (CNSP) stock soars during pre-market. What’s driving it high?


CNS Pharmaceuticals Inc. (NASDAQ: CNSP) stock gained by 2.78% at last close while the CNSP stock price surged by 7.57% in the pre-market trading. CNS Pharmaceuticals is a clinical-stage pharmaceutical business working on anti-cancer medication candidates for the cure of brain and central nervous system tumors, both primary and metastatic. Berubicin, CNSP’s primary medication candidate, is a new anthracycline that seems to penetrate the blood-brain barrier for the first time.

>> 7 Top Picks for the Post-Pandemic Economy << 

What is happening?

WPD Pharmaceuticals is delighted to announce that CNS Pharmaceuticals which is the company that licenses the drug candidate Berubicin to WPD for 29 countries, primarily in Europe, has been given Fast Track Designation by the US Food and Drug Administration (FDA) for the care of patients with reoccurring glioblastoma multiforme (GBM). CNS also acquired Orphan Drug Designation from the FDA for Berubicin, which is used for the treatment of patients with recurrent GBM, as reported earlier.

From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio

The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.

Get our free report, "Top 5 AI Stocks to Buy for 2023".


Read More

Fast Track Designation allows for more regular interactions with the FDA in order to speed up the development and evaluation process for medicines that are supposed to cure serious or life-threatening diseases and have the potential to meet an unmet medical need. Berubicin’s Fast Track Designation from the US Food and Drug Administration is a significant step forward in the development of the drug for the treatment of glioblastoma, the most aggressive, fatal, and treatment-resistant kind of brain cancer. Many patients have few alternatives, and thousands of people die each year as a result of their cancer.CNS now has a faster road to approval for Berubicin, and a clear chance to bring this potentially transformative experimental treatment to market sooner.

>> 7 Top Picks for the Post-Pandemic Economy << 


The initiation of patient recruitment in CNS’s Berubicin trial for the treatment of recurrent glioblastoma multiforme was recently reported. WPD stands to gain a lot from the progress of Berubicin as a GBM therapy because it has the right to manufacture and market the medication candidate in 29 countries.


Please enter your comment!
Please enter your name here